US regulatory system for genetically modified [genetically modified organism (GMO), rDNA or transgenic] crop cultivars (original) (raw)
Related papers
An Introduction to Agricultural Biotechnology Regulation in the U.S
2016
The regulation of agricultural plant and microbial biotechnology products in the United States of America has a rich history that re fl ects the challenges the federal government has faced in the development of appropriate rules and standards needed to determine their safety to humans and the environment. Several factors – the insuf fi cient global food supply, loss or curtailment of the use of older chemis-tries to control pests due to risks and environmental persistence, the rising demand for safer food commodities, and the uncertainty surrounding the sustainability of agriculture in this and other countries – have added to these challenges. The chapter
Technological Forecasting and Social Change, 2005
This paper analyzes the structure and history of regulatory policies in the United States, focusing on recent regulatory changes due to the promise and threat posed by plant-made pharmaceuticals (PMPs). PMPs are the latest advance in the genetic engineering of plants and promise to produce medicines inexpensively and abundantly by using a range of different plants as factories to express active medicinal ingredients; however, PMPs may pose a risk to the public's health if they enter the food supply. How the benefits and risks of PMPs are addressed by the respective government's regulation and how this will affect what, if any, products make it to the marketplace and their ultimate success are of great concern to many different parties, ranging from consumers and farmers to health and food production industries. As a result, this paper addresses the history of agricultural biotechnology regulatory policy since 1972, arguing that three distinct periods may be identified: (1) from 1972 to 1986 when the new biotechnology was focused on scientific self-regulation in the laboratory; (2) from 1987 to 2002, as the technology was being developed and widespread release of certain technologies became more common and was not perceived as an environmental threat, regulations became increasingly laxer; and finally, (3) we argue that we are entering a third phase with a series of controversies over regulatory infractions involving genetically engineered (GE) plants and the potential threats posed by PMPs.
Policy and Governance Perspectives for Regulation of Genome Edited Crops in the United States
Frontiers in Plant Science
Genome editing for crop improvement lies at the leading edge of disruptive bioengineering technologies that will challenge existing regulatory paradigms for products of biotechnology and which will elicit widespread public interest. Regulation of products of biotechnology through the US Coordinated Framework for Biotechnology is predicated on requiring burden of proof that regulation is warranted. Although driven by considerations of newly emerging processes for product development, regulation has, for the most part, focused on characteristics of the biotechnology product itself and not the process used for its development per se. This standard of evidence and product focus has been maintained to date in regulatory considerations of genome edited crops. Those genome edited crops lacking recombinant DNA (rDNA) in the product intended for environmental release, lacking plant pest or pesticidal activity, or showing no food safety attributes different from those of traditionally bred crops are not deemed subject to regulatory evaluation. Regardless, societal uncertainties regarding genome editing are leading regulators to seek ways whereby these uncertainties may be addressed through redefinition of those products of biotechnology that may be subject to regulatory assessments. Within US law prior statutory history, language and regulatory action have significant influence on decision making; therefore, the administrative law and jurisprudence underlying the current Coordinated Framework strongly inform policy and governance when considering new plant breeding technologies such as genome editing.
Chapter 1An Introduction to AgriculturalBiotechnology Regulation in the U.S
2012
The regulation of agricultural plant and microbial biotechnology products in the United States of America has a rich history that re fl ects the challenges the federal government has faced in the development of appropriate rules and standards needed to determine their safety to humans and the environment. Several factorsthe insuf fi cient global food supply, loss or curtailment of the use of older chemistries to control pests due to risks and environmental persistence, the rising demand for safer food commodities, and the uncertainty surrounding the sustainability of agriculture in this and other countries-have added to these challenges. The chapter introduces the U.S. Coordinated Framework for the Regulation of Biotechnology ("Framework"), and the roles of its members: the U.S. Department of Agriculture (USDA), the U.S. Food and Drug Administration (FDA), and the U.S. Environmental Protection Agency (EPA) in regulating agricultural biotechnology in accordance with U.S. federal statutes. The Framework agencies use scienti fi c, risk-based approaches in carrying out their regulatory responsibilities for the products of biotechnology. Relying on their experiences with risk assessment and risk management policies and principles for more conventional products, the Framework agencies have adapted new risk and exposure scenarios into their evaluations to ensure the safe use of these products in agriculture.
Biosafety: evaluation and regulation of genetically modified (GM) crops in the United States
2014
This review of the safety assessment of genetically modified (GM) crops is focused primarily on the process and progress in the United States (US). It reviews the development of the safety evaluation process from the Asilomar conference in 1975 considering issues relevant to recombinant DNA technology, to discussions between the tested and evaluated commercial release for food and feed production. International guidelines were also reviewed for consistency with the US system. The overall process includes consideration of information relating to history of safe or unsafe human and exposure to the gene source and expressed proteins. The primary considerations of safety for dietary proteins are whether or not some consumers are sensitized and have IgE antibodies against the protein encoded by the transgene or whether the transgene represents a risk of eliciting celiac disease. The process considers potential toxic effects of expressed proteins as well as potential impacts on human and animal nutrition. The process in the US is To date there is no evidence that GM crops approved in the US have harmed human or animal consumers. The evaluation takes into account genetic and environmental variation in products produced by plant varieties and is intended to maintain the standard that foods developed from GM plants are intended to be as safe as non-GM genetically similar varieties.
The First Decade of Genetically Engineered Crops in the United States
Ten years after the first generation of genetically engineered (GE) varieties became commercially available, adoption of these varieties by U.S. farmers is widespread for major crops. Driven by farmers' expectations of higher yields, savings in management time, and lower pesticide costs, the adoption of corn, soybean, and cotton GE varieties has increased rapidly. Despite the benefits, however, environmental and consumer concerns may have limited acceptance of GE crops, particularly in Europe. This report focuses on GE crops and their adoption in the United States over the past 10 years. It examines the three major stakeholders of agricultural biotechnology and finds that (1) the pace of R&D activity by producers of GE seed (the seed firms and technology providers) has been rapid, (2) farmers have adopted some GE varieties widely and at a rapid rate and benefited from such adoption, and (3) the level of consumer concerns about foods that contain GE ingredients varies by country,...
The First Decade of Genetically Engineered Crops in the USA
2006
Ten years after the first generation of genetically engineered (GE) varieties became commercially available, adoption of these varieties by U.S. farmers is widespread for major crops. Driven by farmers' expectations of higher yields, savings in management time, and lower pesticide costs, the adoption of corn, soybean, and cotton GE varieties has increased rapidly. Despite the benefits, however, environmental and consumer concerns may have limited acceptance of GE crops, particularly in Europe. This report focuses on GE crops and their adoption in the United States over the past 10 years. It examines the three major stakeholders of agricultural biotechnology and finds that (1) the pace of R&D activity by producers of GE seed (the seed firms and technology providers) has been rapid, (2) farmers have adopted some GE varieties widely and at a rapid rate and benefited from such adoption, and (3) the level of consumer concerns about foods that contain GE ingredients varies by country,...
Revisions to USDA biotechnology regulations: The SECURE rule
Proceedings of the National Academy of Sciences
In keeping with the directive in Executive Order 13874 (Modernizing the Regulatory Framework for Agricultural Biotechnology Products) to adopt regulatory approaches that are proportionate to risk and avoid arbitrary distinctions across like products, the US Department of Agriculture (USDA) revised its biotechnology regulations by promulgating the Sustainable, Ecological, Consistent, Uniform, Responsible, and Efficient (SECURE) rule. Specifically, the SECURE rule 1) establishes exemptions for plants modified by genetic engineering where the modification could otherwise have been made through conventional breeding, 2) uses risk posed by the introduced trait to determine whether an organism is regulated, rather than relying on whether the organism was developed using a plant pest, and 3) provides a mechanism for a rapid initial review to efficiently distinguish plants developed using genetic engineering that do not pose plausible pathways to increased plant pest risk from those that do...
Genetically modified crops: methodology, benefits, regulation and public concerns
British Medical Bulletin, 2000
The genetic modification of crop plants from the methodology involved in their production through to the current debate on their use in agriculture are reviewed. Techniques for plant transformation by Agrobacterium tumefaciens and particle bombardment, and for the selection of transgenic plants using marker genes are described. The benefits of currently available genetically modified (GM) crops in reducing waste and agrochemical use in agriculture, and the potential of the technology for further crop improvement in the future are discussed. The legal requirements for containment of novel GM crops and the roles of relevant regulatory bodies in ensuring that GM crops and food are safe are summarized. Some of the major concerns of the general public regarding GM crops and food: segregation of GM and non-GM crops and cross-pollination between GM crops and wild species, the use of antibiotic resistance marker genes, the prevention of new allergens being introduced in to the food chain and the relative safety of GM and non-GM foods are considered. Finally, the current debate on the use of GM crops in agriculture and the need for the government, scientists and industry to persevere with the technology in the face of widespread hostility is studied.